KRAS and familial pancreatic carcinoma: Dianxu et al (2002) tested 37 of 41 patients (90.2%) with pancreatic cancer positive when plasma Ki-ras mutation analysis was combined with elevated CA 19-9 serum levels (>37 Units ml−1).